Methods for treating cholestasis
Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg/kg/day.
1. A method for treating Alagille Syndrome (ALGS) in a pediatric subject in need of such treatment comprising administering to the subject
(maralixibat chloride), wherein maralixibat chloride is administered in an amount of from about 400 μg/kg/day to about 800 μg/kg/day.
2. The method of claim 1 , wherein maralixibat chloride is administered once daily (QD).
3. The method of claim 1 , wherein maralixibat chloride is administered twice daily (BID).
4. The method of claim 1 , wherein maralixibat chloride is administered for at least 18 weeks.
5. The method of claim 1 , wherein maralixibat chloride is administered for at least 2 years.
6. The method of claim 1 , wherein maralixibat chloride is administered for at least 3 years.
7. The method of claim 1 , wherein the subject exhibits below normal height or weight prior to the administration of maralixibat chloride.
8. The method of claim 1 , wherein the subject experiences pruritus prior to the administration of maralixibat chloride.
9. The method of claim 1 , wherein the subject is at least 1 year of age.
10. The method of claim 1 , wherein maralixibat chloride is administered prior to ingestion of food.
11. The method of claim 1 , wherein maralixibat chloride is administered orally.
12. A method for treating Alagille Syndrome (ALGS) in a pediatric subject in need of such treatment comprising administering to the subject
(maralixibat chloride), wherein maralixibat chloride is administered in an amount of about 400 μg/kg/day.
13. A method for treating Alagille Syndrome (ALGS) in a pediatric subject in need of such treatment comprising administering to the subject
(maralixibat chloride), wherein maralixibat chloride is administered in an amount of about 800 μg/kg/day.